Related references
Note: Only part of the references are listed.Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer
G. Gullo et al.
ANNALS OF ONCOLOGY (2012)
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)
A. Noske et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
Vicente Valero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials
Belinda E. Kiely et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Trastuzumab Single-Drug Therapy after Failure of Cytotoxic Treatment for Metastatic Breast Cancer
Michael Clemens et al.
ONKOLOGIE (2010)
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Neil L. Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease
P Papaldo et al.
ANNALS OF ONCOLOGY (2006)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A retrospective series of long-term survivors of metastatic breast cancer in complete remission
V Amoroso et al.
ONCOLOGY (2005)
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer
EA Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial
J Jassem et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
